SCHEMBL13469710

SCHEMBL13469710

O=Cc1ccc(CCCCc2ccccc2)c2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 9/20 0.42
HDAC1 Q13547 3/20 0.42
HDAC3 O15379 2/20 0.42
HDAC4 P56524 2/20 0.42
HDAC7 Q8WUI4 2/20 0.42
HDAC2 Q92769 2/20 0.42
HDAC10 Q969S8 2/20 0.42
HDAC11 Q96DB2 2/20 0.42
HDAC8 Q9BY41 2/20 0.42
HDAC6 Q9UBN7 2/20 0.42
HDAC9 Q9UKV0 2/20 0.42
HDAC5 Q9UQL6 2/20 0.42
MAPK1 P28482 1/20 0.42
ADRA1A P35348 1/20 0.42
SLC6A3 Q01959 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAOA P21397 1/20 0.40
MAPT P10636 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
MAOB P27338 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13277570 0.98 SIGMAR1 (0.44) SIGMAR1HDAC1HDAC3HDAC4HDAC7
SCHEMBL9491986 0.90 BID (0.47) SIGMAR1MAOAMAPTRXFP1BID
SCHEMBL13465202 0.82 KDM4E (0.55) MAPK1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL13617878 0.82 LIPG (0.47) MAPTTDP1
SCHEMBL28644178 0.82 LIPG (0.47) MAPTTDP1
SCHEMBL2649046 0.81 POLB (0.38) MCL1NPC1RAB9ATDP1
SCHEMBL13278076 0.81 KDM4E (0.53) MAPK1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL13277607 0.81 KDM4E (0.53) MAPK1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL13278055 0.81 KDM4E (0.53) MAPK1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL13469662 0.81 HDAC1 (0.46) SIGMAR1HDAC1HDAC6MAPTRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120264715-A1 SUBSTITUTED BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS ALLERGAN, INC. 2012-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264715-A1 SUBSTITUTED BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS S1PR1, S1PR2, S1PR3 SIGMAR1 115/4885HDAC1 1044/4885HDAC3 1218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.